Last reviewed · How we verify
timolol-dorzolamide fixed combination
At a glance
| Generic name | timolol-dorzolamide fixed combination |
|---|---|
| Also known as | cosopt (MSD) |
| Sponsor | University of Parma |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Dorzolamide+Timolol Multidose Preservative-free vs Dorzolamida+Timolol BAK Preserved Efficacy and Safety (PHASE4)
- Impact of Timolol/Dorzolamide Therapy on Autoregulation in Glaucoma Patients (PHASE4)
- From Preserved, to Preservative-free Cyclosporine 0.1% Enhanced Triple Glaucoma Therapy (NA)
- A 12week, Randomized, Evaluator-Masked, Parallel Group Comparing Evening Dosing Of Xalacom Vs Cosopt In Subj W/ Glaucoma (PHASE4)
- 24-hour Study of Dorzolamide/Timolol and Latanoprost/Timolol Fixed Combinations (PHASE4)
- 24-hour Efficacy and Ocular Surface With Talfuprost and Triple Combined Therapy (PHASE4)
- Clinical Study of A Fixed Combination of Timolol-Brimonidine-Dorzolamide (PHASE2)
- Choroidal Thickness and Its Correlations With Ocular Parameters in Primary Open-angle Glaucoma (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- timolol-dorzolamide fixed combination CI brief — competitive landscape report
- timolol-dorzolamide fixed combination updates RSS · CI watch RSS
- University of Parma portfolio CI